Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen N. Moore, Paul DiSilvestro, Nicoletta Colombo et al.|New England Journal of Medicine|2018Cited by 2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialÉric Pujade-Lauraine, Thibault De La Motte Rouge, Jonathan A. Ledermann et al.|The Lancet Oncology|2017Cited by 1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Isabelle Ray‐Coquard et al.|The Lancet Oncology|2021Cited by 412
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 TrialPaul DiSilvestro, Kathleen N. Moore, Nicoletta Colombo et al.|Journal of Clinical Oncology|2020Cited by 122
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.Andrés Poveda, Éric Pujade-Lauraine, Anne Floquet et al.|Journal of Clinical Oncology|2020Cited by 110